uniQure Announces Pricing of its Public Offering
LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...
UniQure Prices 4.4 Mln Offering At $17/Share, Stock Down In Pre-Market
Wednesday announced the pricing of underwritten public offering of around 4.4 million shares at $17 per share, ...
uniQure Announces Proposed Public Offering
LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...
uniQure Inc.: uniQure Announces Pricing of its Public Offering
LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...
uniQure (NASDAQ:QURE) Shares Gap Down – Here’s What Happened
Qure (NASDAQ:QURE – Get Free Report) shares gapped down before the market opened on Friday . The stock had previously closed at $18.05, but opened at $17.55. uniQure shares last traded at $17.73, with ...
SA Asks: Which biotechs are most likely to be acquired near-term?
Last year's first quarter saw a flurry of biotech takeover deals, starting off with Johnson & Johnson (JNJ)/Ambrx, Merck (MRK)/Harpoon, GSK (GSK)/Aiolos and Novartis(NVS)/Calypso in early January.
pharmaphorum5d
uniQure rockets on map to market for Huntington's therapy
uniQure's Nasdaq-listed shares rose 110% to $15.30 after news of the agreement with the FDA was announced, giving the company a value of almost $750 million. Last month, it started a cost ...